Harmony Biosciences Holdings, Inc.

    Jurisdiction
    United States
    ISIN
    US4131971040 (HRMY)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    €100.12 ∞% undervalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Read full profile

    Fundamentals

    Net revenue
    €658.93M
    Gross margin
    78.3%
    EBIT
    €189.24M
    EBIT margin
    28.7%
    Net income
    €154.30M
    Net margin
    23.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €835.70M +26.8% €206.72M +34.0%
    €944.63M +13.0% €239.94M +16.1%
    €1.10B +16.6% €311.63M +29.9%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Kapadia Sandip CHIEF FINANCIAL OFFICER -22K $36.50 -$787.41K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 840K $27.89M +272K Buy

    Earnings Calls

    Latest earnings call: November 1, 2023 (Q3 2023)

    Add to watchlist

    Notifications